FIELD: biotechnology.
SUBSTANCE: present invention relates to immunology. Disclosed are versions of a human neutralizing anti-IL-33 monoclonal antibody, as well as a nucleic acid coding molecule, a vector, a host cell and a method of producing said antibody variants. Invention also discloses a composition for inhibiting expression of INF-gamma, IL-5, IL-6 or IL-13 cytokines, as well as a pharmaceutical composition for treating, preventing or ameliorating diseases associated with IL-33.
EFFECT: present invention can find further application in therapy, including inflammatory diseases.
15 cl, 11 dwg, 14 tbl, 28 ex
Title | Year | Author | Number |
---|---|---|---|
RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USING | 2006 |
|
RU2444528C2 |
IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
HUMANISED ANTIBODIES TO Toll-LIKE RECEPTORS 2 AND THEIR APPLICATIONS | 2010 |
|
RU2563344C2 |
ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS | 2011 |
|
RU2533809C9 |
MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
PEPTIDE VACCINES AGAINST INTERLEUKIN-31 | 2019 |
|
RU2786441C2 |
Authors
Dates
2019-12-19—Published
2014-12-26—Filed